he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-04-282013年全球性抗癫痫联合会抗癫痫药使用指南
- 2022-04-25女性癫痫,这些问题你有非议吗?
- 2022-04-06FDA批准Aptiom用于治疗患者癫痫发作
- 2022-02-07未满癫痫病病因有哪些
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- FDA警告怀孕期间使用丙戊酸钠药物
- 第一次同房失败,怎么治疗?
- FDA批准Aptiom用于治疗患者癫痫发作
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫猝死:凶手是谁?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 乳腺增生结节疏通茶 | 改善月经前胀痛
- 卵巢早衰妇女的福音 ----原始卵泡体外激活技术(IVA)
- 癫痫患者手术评估新型工具
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- J Orthop Trauma:髌腱内侧入路胫骨髓内钉术后膝前痛与髓钉突起有关
- NEURON:纤维蛋白原诱导阿尔茨海默病的认知障碍
- FDA批准塞尔基因Otezla治疗银屑病性关节炎
- 运动或帮助保护1型糖尿病患者β细胞功能
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 黑芝麻的营养价值 吃黑芝麻的好处
- Annals of Neurology:急性后遗症主要涉及哪些系统?
- 月经期间要注意 有些药物和食物不能食用
- 揭露手指月牙的东西 拇指经常有小指(8)
- 2015 神经系统疾病诊疗进展
- 2015第31届国际癫痫大会(IEC)
- 私密┃我说同房疼,医生说我有妇科病?
- 什么是马齿苋? 马齿苋的功效和作用是什么?
- 为什么身上有小白点 可能得了这种病?
- 北京妇产医院首都医科大学第九届妇科内镜技术手拉手培训班
- 老年人爱打瞌睡、喜好“回忆往事”,还要注意这种情况!
- 治疗法癫痫病偏方哪些好啊
- 怎么疗法癫痫病
- 病症治疗 中医疗法治疗病症不用愁
- 儿童癫痫病的发病征状都有哪些
- 女性癫痫病怎么外科手术好
- 孕妇癫痫病但会严重吗
- 20130730云南养生会:沈洪俊讲癫痫病的现代症状
- 哮喘病小发作症状 这些症状就是哮喘小发作
- 表征为什么要定期复查
- 妇女癫痫病的怎么治疗
- 癫痫病症状 怎样护理人员癫痫病人